Tolvaptan and Conventional Treatment for Acute Decompensated Heart Failure

Tolvaptan and Conventional Treatment for Acute Decompensated Heart Failure - Tolvaptan and Conventional Treatment for Acute Decompensated Heart Failure

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000018081

Enrollment

Registered

2015-06-25

Start date

2012-11-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute decompensated heart failure

Interventions

Administration of Tolvaptan within 24 hours from admission Attending physician determine the dose and the duration of administration. Dosing up Furosemide within 24 hours from admission Attending ph

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Acute decompensated heart failure patients diagnosed by Framingham criteria 2. Patients who are able to take oral medications 3. Serum sodium < 146 mEq/L at allocation 4. Patients who are able to provide consent

Exclusion criteria

Exclusion criteria: 1. Patients with hypersensitivity to Tolvaptan and the analogous compounds 2. Hemodialysis 3. Disability to appeal thirsty 4. Serum sodium > 145 mEq/L at allocation 5. Pregnancy 6. Acute coronary syndrome 7. Patients who attending physicians consider to be inappropriate due to other reasons mentioned above

Design outcomes

Primary

Measure	Time frame
Defined length of hospital stay Occurrence rate of worsening renal function	—

Secondary

Measure	Time frame
Event rate (cardiac death, readmission for heart failure) Urinary volume Dosage of Furosemide	—

Countries

Japan

Contacts

Public ContactKazuhiro Kimura

Shinshu University Department of Cardiovascular Medicine

kaz_kimura@shishu-u.ac.jp0263-37-3486

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026